Soleno Therapeutics, Inc.

NasdaqCM:SLNO Stock Report

Market Cap: US$2.8b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Soleno Therapeutics Management

Management criteria checks 2/4

Soleno Therapeutics' CEO is Anish Bhatnagar, appointed in Jan 2017, has a tenure of 9.33 years. total yearly compensation is $8.87M, comprised of 8.3% salary and 91.7% bonuses, including company stock and options. directly owns 0.82% of the company’s shares, worth $22.74M. The average tenure of the management team and the board of directors is 2 years and 2.8 years respectively.

Key information

Anish Bhatnagar

Chief executive officer

US$8.9m

Total compensation

CEO salary percentage8.33%
CEO tenure9.3yrs
CEO ownership0.8%
Management average tenure2yrs
Board average tenure2.8yrs

Recent management updates

Recent updates

Seeking Alpha • Mar 21

Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory

Summary Soleno Therapeutics is nearing FDA approval for its lead drug, DCCR, targeting Prader-Willi Syndrome, a rare genetic condition with no current FDA-approved treatments. Despite positive analyst ratings and a strong cash position, insider selling and competition from companies like Aardvark Therapeutics and Acadia Pharmaceuticals raise concerns. The PWS market is valued at $600 million, but Soleno's $2.2 billion market cap seems inflated given its limited pipeline and looming competition. An analysis around Soleno Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Analysis Article • Feb 26

We're Hopeful That Soleno Therapeutics (NASDAQ:SLNO) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Nov 08

Companies Like Soleno Therapeutics (NASDAQ:SLNO) Can Afford To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 10

Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments

Summary Soleno Therapeutics' DCCR shows promising results in reducing hyperphagia in PWS patients. I believe its FDA approval is likely by December 27, 2024. DCCR could become the first approved treatment for PWS hyperphagia, addressing a significant unmet medical need. DCCR's unique mechanism targets PWS hyperphagia while preserving lean mass. This potentially extends its use beyond PWS to weight loss, enhancing SLNO's market prospects. SLNO's robust cash position and recent equity raise ensure sufficient funding for DCCR's commercialization, reducing near-term dilution risks. Despite inherent biotech and market adoption risks, SLNO's favorable regulatory outlook and first-mover advantage in treating PWS hyperphagia justify a 'Strong Buy' rating. Read the full article on Seeking Alpha
Analysis Article • Mar 08

We're Not Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn

Just because a business does not make any money, does not mean that the stock will go down. For example, Soleno...

CEO Compensation Analysis

How has Anish Bhatnagar's remuneration changed compared to Soleno Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

US$96m

Dec 31 2025US$9mUS$739k

US$20m

Sep 30 2025n/an/a

-US$78m

Jun 30 2025n/an/a

-US$181m

Mar 31 2025n/an/a

-US$198m

Dec 31 2024US$51mUS$640k

-US$176m

Sep 30 2024n/an/a

-US$131m

Jun 30 2024n/an/a

-US$65m

Mar 31 2024n/an/a

-US$52m

Dec 31 2023US$4mUS$557k

-US$39m

Sep 30 2023n/an/a

-US$33m

Jun 30 2023n/an/a

-US$28m

Mar 31 2023n/an/a

-US$27m

Dec 31 2022US$1mUS$557k

-US$24m

Sep 30 2022n/an/a

-US$21m

Jun 30 2022n/an/a

-US$23m

Mar 31 2022n/an/a

-US$28m

Dec 31 2021US$4mUS$538k

-US$31m

Sep 30 2021n/an/a

-US$31m

Jun 30 2021n/an/a

-US$31m

Mar 31 2021n/an/a

-US$28m

Dec 31 2020US$3mUS$504k

-US$25m

Sep 30 2020n/an/a

-US$36m

Jun 30 2020n/an/a

-US$27m

Mar 31 2020n/an/a

-US$30m

Dec 31 2019US$822kUS$470k

-US$31m

Compensation vs Market: Anish's total compensation ($USD8.87M) is about average for companies of similar size in the US market ($USD7.04M).

Compensation vs Earnings: Anish's compensation has been consistent with company performance over the past year.

CEO

Anish Bhatnagar (55 yo)

9.3yrs
Tenure
US$8,872,611
Compensation

Dr. Anish Bhatnagar, M.D. has been Chief Executive Officer and Director of Soleno Therapeutics, Inc. since 2017 and serves as its President and was its Chief Operating Officer. He serves as Chairman of Sol...

Leadership Team

NamePositionTenureCompensationOwnership
Anish Bhatnagar
Chairman9.3yrsUS$8.87m0.82%
$ 22.7m
James MacKaness
Executive Officerless than a yearUS$2.79m0.18%
$ 4.9m
Meredith Manning
Chief Commercial Officer2.3yrsUS$2.61m0.011%
$ 302.5k
Kevin Norrett
Chief Business Officerless than a yearUS$3.80m0%
$ 0
Manher Joshi
Chief Development Officerless than a yearUS$4.16m0%
$ 0
Jennifer Fulk
Chief Financial Officerless than a yearno datano data
Jesse Schumaker
General Counsel1.6yrsno datano data
Lauren Budesheim
Senior Vice President of People2.3yrsno datano data
Kristen Yen
Senior Vice President of Global Clinical Operations and Patient Advocacyno dataUS$821.67k0.072%
$ 2.0m
Neil Cowen
Senior Vice President of New Product Planning9.2yrsno datano data
Patricia Hirano
Senior Vice President of Regulatory Affairsno dataUS$6.05m0.044%
$ 1.2m
Michael Huang
Senior Vice President of Clinical Development2.5yrsno data0.047%
$ 1.3m
2.0yrs
Average Tenure
55yo
Average Age

Experienced Management: SLNO's management team is not considered experienced ( 2 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Anish Bhatnagar
Chairman12.3yrsUS$8.87m0.82%
$ 22.7m
James Arthur Geraghty
Member of Advisory Board2.3yrsno datano data
Thomas Casale
Member of Advisory Boardno datano datano data
Andrew Sinclair
Independent Director7.4yrsUS$300.20k0%
$ 0
Robert Christensen
Member of Advisory Boardno datano datano data
Vinod Bhutani
Member of Advisory Boardno datano datano data
Birgitte Volck
Independent Director6.9yrsUS$360.48k0.026%
$ 718.1k
Glenis Scadding
Member of Advisory Boardno datano datano data
Matthew Pauls
Lead Independent Director2.8yrsUS$390.34k0%
$ 0
Shamim Ruff
Chair of the Development Advisory Board2.3yrsno datano data
David Stevenson
Member of Advisory Boardno datano datano data
Dawn Bir
Independent Director1.8yrsUS$350.61k0.076%
$ 2.1m
2.8yrs
Average Tenure
55yo
Average Age

Experienced Board: SLNO's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/19 07:01
End of Day Share Price 2026/05/15 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Soleno Therapeutics, Inc. is covered by 7 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
François BriseboisCraig-Hallum Capital Group LLC
Paul ChoiGoldman Sachs